SCHEMBL2020897

SCHEMBL2020897

O=Cc1ccc(-c2ccc3c(c2)C(=O)NC3)s1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 12/20 0.65
NTRK2 Q16620 2/20 0.52
CLK4 Q9HAZ1 2/20 0.52
DYRK1B Q9Y463 2/20 0.52
TYRO3 Q06418 1/20 0.52
JAK2 O60674 1/20 0.51
NTRK1 P04629 1/20 0.51
MET P08581 1/20 0.51
FGFR1 P11362 1/20 0.51
PRKACA P17612 1/20 0.51
KDR P35968 1/20 0.51
MAP2K2 P36507 1/20 0.51
FLT3 P36888 1/20 0.51
GSK3B P49841 1/20 0.51
MAP2K1 Q02750 1/20 0.51
MST1R Q04912 1/20 0.51
NTRK3 Q16288 1/20 0.51
CAMK1D Q8IU85 1/20 0.51
FYN P06241 1/20 0.48
PGR P06401 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019635 0.89 PRF1 (0.68) PRF1CLK4NTRK1FLT3GSK3B
SCHEMBL2039248 0.86 PRF1 (0.67) PRF1PGRMAPT
SCHEMBL15571716 0.80 CLK4 (0.55) PRF1NTRK2CLK4DYRK1BTYRO3
SCHEMBL20923875 0.80 CLK4 (0.57) PRF1NTRK2CLK4DYRK1BTYRO3
SCHEMBL14761476 0.80 PRF1 (1.00) PRF1
SCHEMBL14761477 0.80 PRF1 (1.00) PRF1
SCHEMBL12633692 0.80 PRF1 (1.00) PRF1
SCHEMBL2020380 0.78 PRF1 (0.67) PRF1
SCHEMBL2038301 0.77 PRF1 (0.64) PRF1PGRMAPT
SCHEMBL18546224 0.76 PRF1 (0.65) PRF1PGRMAPTCYP2E1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2013-03-14 US disclosed
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2013-03-14 US disclosed
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2013-03-14 US disclosed
EP-2515903-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF Peter MacCallum Cancer Institute (AU) 2012-10-31 EP disclosed
WO-2011075784-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PRF1, GZMB, SERPINB1 PRF1 1/4885NTRK2 3597/4885CLK4 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.